Picodya Technologies News
5 articles
growth-positive
Picodya diagnostics system adopted through NIH pandemic initiative
Israel-based in vitro diagnostics firm, Picodya, has announced that its B-Matrix multiplexed point-of-care testing systems are being implemented in government laboratories across the US. The adoption by the National Institute of Health (NIH) is part of a bid to establish a backlog of immunobiological countermeasures in preparation for another pandemic. The NIH initiative, named PREMISE and headed up by the National Institute of Allergy and Infectious Diseases (NIAID), launched in 2021 and saw the body working alongside Picodya to install the B-Matrix systems at NIAID Vaccine Research Centers and laboratories.
PartnersExpand
Game Changing Immunoassay Platform Redefines POC Diagnostics on Every Level
growth-positive
Covid brings Picodya's rapid diagnostics out from under the radar
Kibbutz Hatzerim, known for its irrigation technology company Netafim, has diversified its investments and is now involved in medical diagnostics through its investment in Picodya. Picodya, led by Tzvika Barkai, has developed a prototype for a diagnostic product that can perform multiple tests on a patients sample simultaneously, at a lower cost. The product has undergone feasibility tests for twenty types of symptoms and diseases and is expected to reach the market in 2022-2023. Kibbutz Hatzerim provides the organizational and management framework for Picodya, which recently completed a $10 million fundraising round led by SIBF. The kibbutz aims to become an industrial product company in the future.
InvestmentExpand
growth-positive
Hatzerim-based Picodya raises $10 million for rapid diagnostics innovation
Picodya, an Israeli company, is on the verge of completing a $10 million funding round led by SIBF. The company has developed an in vitro diagnostics platform named B-Matrix, which can conduct tests and analyses for multiple patients simultaneously. The goal is to deploy the product at the point of care to reduce the time and manpower required for blood tests. Picodya has received grants from the Israel Innovation Authority and its prototype will be tested by The Israel Institute for Biological Research. The funding round is part of preparations for a larger round aimed at raising tens of millions of dollars in the next year to 18 months.
Investment
Neutral
https://www.web24.news/u/2020/08/an-israeli-company-can-diagnose-covid-19-in-multiple-patients-simultaneously-in-just-15-minutes.html
The webpage was created by the domain owner using Sedos Domain Parking service. Sedo, however, maintains no relationship with third party advertisers and does not control or endorse any specific service or trade mark.
